World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 2801
Fax direct: +41 22 791 4836
E-mail : diagnostics@who.int

In reply please refer to: GP/

Your reference: P17-370-9

Zalgen Labs LLC.
For the attention of Mr Douglass Simpson
Senior Advisor
20271 Goldenrod Lane, Suite 2083
Germantown
MD 20876
Etats Unis d'Amériques

19 October 2018

Dear Mr Simpson,

Subject: WHO Emergency Use Assessment and Listing Procedure - Delisting
Product name: ReEBOV™ Antigen Rapid Test Kit
EUAL number: **EA 0011-011-00**

Thank you for the letter dated 19 June 2018 stating the discontinuation of the labelling and commercializing of the above-referenced product for emergency use.

Please be advised that based on the provided information the ReEBOV™ Antigen Rapid Test Kit will be de-listed from the WHO Emergency Use Assessment and Listing for Ebola Virus Diseases In Vitro Diagnostics with immediate effect.

If you have any questions, please do not hesitate to contact us by email (diagnostics@who.int). We thank you for having shown interest in the prequalification of your product.

Yours sincerely,

Mr Deus Mubangizi
Coordinator
Prequalification Team
Regulation of Medicines and other Health Technologies